60.20
-0.17%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AnnJi Pharmaceutical Co
Its shares trade on Taipei Exchange under the ticker 7754.TWO. It has been listed since 25 June 2024. In the fiscal year to 31 December 2025, it reported revenue of TWD 7.6m and a net loss of TWD 357.9m. At that date it held total assets of TWD 590.1m and shareholders' equity of TWD 319.8m.
AnnJi Pharmaceutical Co Ltd is a TW-based company operating in Pharmaceuticals industry. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-06-25. AnnJi Pharmaceutical Co Ltd is a Taiwan-based company mainly focuses on innovative new drug projects with high chances of success, and concentrates resources on the development of three main axes, including nuclear factor E2-related factor 2 (Nrf2) activator (AJ201), highly selective histone deacetylase 6 (HDAC6) inhibitor (AJ302), and next-generation androgen degradation promoter (AJ202). AJ201 oral suspension is used to treat neurodegenerative diseases caused by polyglutamine (polyQ), among which spinal and bulbar muscular atrophy (SBMA) is the first disease to be verified by clinical concept. AJ302 sustained-release injection is used to treat peripheral neuritis caused by chemotherapy. AJ202 scalp topical is used to treat male pattern baldness. Its products are mainly sold to European and American markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 2024
- Employees
- 34
- Website
- ajpharm.com ↗
Leadership
Pay as last reported
- Ms. Wenying HuangChairman of the Board, General Manager
- Rongyi HuangDirector
- Zhilong ShenDirector
- Mr. Mon Lin TsaiDirector
- Zhixuan ZhuangDirector
- Mr. Jaw-Jou KangIndependent Director
- Mr. Jing-Ping LiouIndependent Director
- Ms. Yu-Hui SuIndependent Director
- Zhenwu ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AnnJi Pharmaceutical's AJ201 targets neurodegenerative diseases with clinical validation for SBMA in Europe and America.
- AJ302 treats chemotherapy-induced peripheral neuritis with sustained-release injection technology in the US market.
- AJ202 addresses male pattern baldness with scalp topical formulation for North American consumers.
Weaknesses
- Limited employee count of 34 restricts research and development capacity for a pharmaceutical company.
- Newly listed on 25 June 2024 with no established market presence in Asia-Pacific regions.
- Dependence on three product lines for revenue without diversified portfolio in Health Care sector.
Opportunities
- Expanding market for Nrf2 activators in neurodegenerative disease treatment across Europe and America.
- Growing demand for HDAC6 inhibitors in chemotherapy-related peripheral neuritis treatment in US.
- Increasing consumer interest in next-generation androgen degradation promoters for hair loss solutions.
Threats
- Competition from established pharmaceutical firms in the European and American markets.
- Regulatory challenges for new drug approvals in the US and European regulatory bodies.
- Market volatility affecting pharmaceutical product adoption in North American and European regions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.